erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
.
the total amount paid out in critical illness claims was £75.19m, with cancer accounting for 74 per cent of claims from women, mainly breast cancer, alongside 51 per cent from men.
.
.
.
.
.